{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:57:20Z","timestamp":1790708240250,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K24DA022412"],"award-info":[{"award-number":["K24DA022412"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["PAR-07-232"],"award-info":[{"award-number":["PAR-07-232"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA024549"],"award-info":[{"award-number":["R01DA024549"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA024550"],"award-info":[{"award-number":["R01DA024550"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA024553"],"award-info":[{"award-number":["R01DA024553"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA024554"],"award-info":[{"award-number":["R01DA024554"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA024555"],"award-info":[{"award-number":["R01DA024555"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.jsat.2017.01.018","type":"journal-article","created":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T16:00:18Z","timestamp":1487779218000},"page":"61-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?"],"prefix":"10.1016","volume":"85","author":[{"given":"Peter D.","family":"Friedmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward V.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Randall","family":"Hoskinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean M.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Bonnie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara Y.","family":"Boney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles P.","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jsat.2017.01.018_bb0005","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMsa064115","article-title":"Release from prison\u2014A high risk of death for former inmates","volume":"356","author":"Binswanger","year":"2007","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.jsat.2017.01.018_bb0010","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1001\/jama.2008.976","article-title":"Treating drug abuse and addiction in the criminal justice system: Improving public health and safety","volume":"301","author":"Chandler","year":"2009","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jsat.2017.01.018_bb0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2014a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol","year":"1990","journal-title":"Health Policy"},{"issue":"1","key":"10.1016\/j.jsat.2017.01.018_bb0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/08897077.2011.611460","article-title":"Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): Availability, barriers, and intentions","volume":"33","author":"Friedmann","year":"2012","journal-title":"Substance Abuse"},{"issue":"3","key":"10.1016\/j.jsat.2017.01.018_bb0025","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jsat.2006.12.020","article-title":"Evidence-based treatment practices for drug-involved adults in the criminal justice system","volume":"32","author":"Friedmann","year":"2007","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"13","key":"10.1016\/j.jsat.2017.01.018_bb0030","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","article-title":"Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial","volume":"293","author":"Garbutt","year":"2005","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jsat.2017.01.018_bb0035","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/08897077.2014.902787","article-title":"Buprenorphine treatment for probationers and parolees","volume":"36","author":"Gordon","year":"2015","journal-title":"Substance Abuse"},{"issue":"2\u20133","key":"10.1016\/j.jsat.2017.01.018_bb0040","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.drugalcdep.2007.05.022","article-title":"A randomized clinical trial of methadone maintenance for prisoners: Results at 1-month post-release","volume":"91","author":"Kinlock","year":"2007","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2017.01.018_bb0045","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cct.2015.01.005","article-title":"Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: Rationale and design of a randomized controlled effectiveness trial","volume":"41","author":"Lee","year":"2015","journal-title":"Contemporary Clinical Trials"},{"issue":"13","key":"10.1016\/j.jsat.2017.01.018_bb0050","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","article-title":"Extended-release naltrexone to prevent opioid relapse in criminal justice offenders","volume":"374","author":"Lee","year":"2016","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.jsat.2017.01.018_bb0055","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/08897077.2011.609446","article-title":"A randomized trial of methadone initiation prior to release from incarceration","volume":"33","author":"McKenzie","year":"2012","journal-title":"Substance Abuse"},{"issue":"3","key":"10.1016\/j.jsat.2017.01.018_bb0060","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0740-5472(92)90062-S","article-title":"The fifth edition of the addiction severity index","volume":"9","author":"McLellan","year":"1992","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"3","key":"10.1016\/j.jsat.2017.01.018_bb0065","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/ADM.0000000000000125","article-title":"Treating opioid dependence with injectable extended-release naltrexone (XR-NTX): Who will respond?","volume":"9","author":"Nunes","year":"2015","journal-title":"Journal of Addiction Medicine"},{"issue":"5","key":"10.1016\/j.jsat.2017.01.018_bb0070","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/jcp.0b013e31814ce50d","article-title":"Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment","volume":"27","author":"O'Malley","year":"2007","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1016\/j.jsat.2017.01.018_bb0075","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1530-0277.2007.00347.x","article-title":"Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial","volume":"31","author":"O'Malley","year":"2007","journal-title":"Alcoholism, Clinical and Experimental Research"},{"issue":"4","key":"10.1016\/j.jsat.2017.01.018_bb0080","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJMra1604339","article-title":"Treatment of opioid-use disorders","volume":"375","author":"Schuckit","year":"2016","journal-title":"The New England Journal of Medicine"},{"issue":"Suppl. 20","key":"10.1016\/j.jsat.2017.01.018_bb0085","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"6","key":"10.1016\/j.jsat.2017.01.018_bb0090","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/10550490802409074","article-title":"Gender differences in predictors of treatment attrition with high dose naltrexone in cocaine and alcohol dependence","volume":"17","author":"Suh","year":"2008","journal-title":"The American Journal on Addictions"},{"issue":"4","key":"10.1016\/j.jsat.2017.01.018_bb0095","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3109\/00952999209051037","article-title":"High-risk sexual behaviors of intravenous drug users in- and out-of-treatment: Implications for the spread of HIV infection","volume":"18","author":"Watkins","year":"1992","journal-title":"The American Journal of Drug and Alcohol Abuse"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547216305049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547216305049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:47:27Z","timestamp":1760039247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547216305049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":19,"alternative-id":["S0740547216305049"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2017.01.018","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2017.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}